Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

Katherine Bowdish, vice president of global R&D at Sanofi and leader of Sunrise, the French big pharma's early-stage investment arm, talks to Scrip about living vicariously through biotech companies whilst having the power and backing of a pharma major to advance important, innovative science.

AbbVie pays $595m up front for rights to Boehringer's Phase III anti-IL-23 candidate, which it sees as a potential competitor to Stelara. Merck and Sanofi end their European vaccines joint venture after a 22-year run.